Machanism of action (MoA)
ASD001 suppresses innate immune functions by activating CD11b on innate immune cells. ASD001 can help to restore intestinal barrier homeostasis during barrier breach by reverting innate immune cells to immune suppressive phenotypes and an increase in IL-10 production and decrease in TNF-a secretion. In addition, ASD001 can also suppress neutrophil extracellular traps formation, leading to a reduction in further tissue damage.
Partner of choice for novel immunotherapeutics
Ascendo Biotechnology is a strategic partner of choice for novel immunotherapies which exploit the interplay between the innate and adaptive immune response. We are currently seeking partners to accelerate the development and commercialization of our lead oncology drug, ASD141.
If you’re interested in discussing our programmes, please get in touch